Trial reportJournal of the American Heart Association2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.
Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00867048 (Strategic Timing of AntiRetroviral Treatment), which is not on this map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Strategic Timing of AntiRetroviral Treatment
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Characterization and stratification of risk factors of stroke in people living with HIV: A theory-informed systematic review.BMC cardiovascular disorders · 2025Pooled it
- Characterization and risk stratification of coronary artery disease in people living with HIV: a global systematic review.Frontiers in cardiovascular medicine · 2025Pooled it
- Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis.BMC cardiovascular disorders · 2017Pooled it
- Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.Progress in cardiovascular diseasesPooled it
- Trial
- Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.Drugs in R&D · 2018Trial
- Beyond HIV: investigating key drivers of metabolic syndrome in midlife women with HIV in the INSTI era.AIDS research and therapy · 2026Article
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Early versus deferred antiretroviral therapy initiation and long-term cardiovascular disease outcomes in people with HIV: The START study.Open forum infectious diseases · 2025Article
- The heart and HIV therapy: exploring the dual cardiovascular impact of antiretroviral treatment - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults.Current atherosclerosis reports · 2025Review
- Global health solidarity in the HIV and hypertension disease response.AIDS (London, England) · 2025Article
- Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study.Open forum infectious diseases · 2025Article
- Article
- Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.Journal of the International AIDS Society · 2024Article
- Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.American journal of preventive cardiology · 2024Review
- Connection Between HIV and Mitochondria in Cardiovascular Disease and Implications for Treatments.Circulation research · 2024Review
- IL-32 Drives the Differentiation of Cardiotropic CD4+ T Cells Carrying HIV DNA in People With HIV.The Journal of infectious diseases · 2024Article
- Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.The Pan African medical journal · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 14 institutions in 7 countries.
Funding
Abstract
introductionHIV infection and certain antiretroviral therapy (ART) medications increase atherosclerotic cardiovascular disease risk, mediated, in part, through traditional cardiovascular disease risk factors. METHODS AND
resultsWe studied cardiovascular disease risk factor changes in the START (Strategic Timing of Antiretroviral Treatment) trial, a randomized study of immediate versus deferred ART initiation among HIV-positive persons with CD4
conclusionsAmong HIV-positive persons with preserved immunity, immediate ART led to increases in total cholesterol and low-density lipoprotein cholesterol but also concurrent increases in high-density lipoprotein cholesterol and decreased use of blood pressure medications. These opposing effects suggest that, in the short term, the net effect of early ART on traditional cardiovascular disease risk factors may be clinically insignificant." CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00867048.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.